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Purpose: The clinical features, treatment modality appro-
aches in clinical practice, and prognostic factors for anal
canal carcinoma patients were retrospectively analyzed.
Materials and Methods: Between October 1994 and
December 2005, 50 patients with anal canal cancer were
treated at Samsung Medical Center, Seoul, Korea. Results:
After a median follow up of 37.8 months (range, 6.6 - 136.1
months), the 5-year and 10-year survival rates for the 38
patients with early and locally advanced squamous and
cloacogenic carcinoma (squamous cell carcinoma and
cloacogenic carcinoma) were 74.8% and 66.5%, respectively.
The 5-year survival and disease-free survival rates (DFS) of
the 31 patients who received chemoradiation therapy (CRT)
were 83.6% and 74.3%, respectively. The overall and DFS
could not be determined for the adenocarcinoma group due to
the small number of cases (n = 8). Univariate analysis showed
that tumor size (p = 0.04) and inguinal node status (p = 0.04)
significantly influenced patient survival in patients with
squamous cell and cloacogenic carcinomas. Furthermore,
univariate analysis also showed that, inguinal node status
influenced patient survival in the adenocarcinoma group.
Multivariate analysis showed that inguinal node metastasis is
a single independent prognostic variable for survival (p =
0.04) in patients with squamous cell and cloacogenic
carcinomas. Conclusion: Combined CRT has been adopted as
standard treatment with outcomes that are comparable to
those reported in randomized clinical trials. Due to the rarity
and complexity of anal canal carcinoma, interdepartmental
cooperation is required for disease treatment. Thus, proper
treatment of patients should incorporate a team-approach and
should be available to as many patients as possible.
Key Words: Anal canal cancer, neoplasm, chemotherapy,
radiotherapy
INTRODUCTION
Anal canal cancer is rare and only accounts for
1% to 6% of all anorectal malignancies.
1 The
pathogenesis and treatment of anal canal cancer
has undergone substantial reassessments over the
past few decades. The current goals of anal
cancer treatment are controlling the disease
locally, salvaging the sphincter, and avoiding the
need for a permanent colostomy. Nigro et al.
2
reported the first successful use of concurrent
chemoradiation (CCRT) in an attempt to downstage
a locally advanced tumor in a patient before an
abdominoperineal resection (APR). Since then,
chemoradiation therapy has become the standard
treatment for anal cancer, even for early disease.
Surgery is only recommended for those patients
who do not achieve a complete clinical response
to primary chemoradiation.
3,4 Results from three
subsequent randomized trials
5-7 demonstrated that
concurrent chemoradiotherapy with mitomycin
and 5-FU had superior results compared to
radiotherapy alone in controlling the local disease
and improving survival rates. The trial conducted
by the European Organization for Research and
Treatment of Cancer (EORTC)
6 also showed the
superiority of concomitant 5-FU/mitomycin and
radiotherapy treatments compared to using
radiotherapy alone.
In this study, we retrospectively analyzed the
clinical features, treatment modality approaches in
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clinical practice, and prognostic factors in anal
canal carcinoma patients.
MATERIALS AND METHODS
Patients
Between October 1994 and December 2005, 50
patients with anal canal cancer were treated at
Samsung Medical Center, Seoul, Korea. The
following data were thoroughly reviewed and
collected from the medical records for analyses:
demographics, histological type, clinical stage,
vital status, recurrence, treatment modality, and
treatment outcome. The main outcome measures
were treatment response rate and overall survival.
Patients were clinically staged according to the
American Joint Committee on Cancer (AJCC)
TNM staging system.
8 Tumor assessments con-
sisted of digital rectal examination, colonoscopy,
and abdominopelvic CT scan. Rectal MRI and
endorectal ultrasonography were performed as
indicated.
Tumor response was assessed 6 weeks after the
completion of the CCRT. The criteria for deter-
mining response were as follows: 1) complete
response (CR) was defined as the clinical dis-
appearance of the tumor, 2) partial response (PR)
was defined as a 50% or greater reduction in the
largest tumor diameter, and 3) failure of the CCRT
regimen or progressive disease was defined as an
25% or greater increase in the largest tumor
diameter or the appearance of new lesions.
Only the records of patients whose tumor
involved the anal canal (defined as 0 - 4 cm from
the anal verge) were considered. If > 50% of the
tumor length was proximal to this region, patients
were considered to have adenocarcinoma of the
rectum and therefore were excluded. In an
attempt to eliminate the rectal cancers from the
group, hematoxylin-eosin stained slides were
reviewed to distinguish between tumors of the
rectal mucosa and anal duct origin.
The patient characteristics are outlined in Table
1. Bleeding, with or without perianal pain, was
the most common presenting symptom (40.0%)
followed by anal pain (18.0%).
Chemoradiation therapy
The primary treatment modality for 39 patients
(78.0%) was CCRT. Thirty patients received a
continuous infusion of 5-FU (1000 mg/m
2 daily on
days 1 - 4 and 29 - 32 of radiation therapy) and a
short infusion of 10 mg/m
2 mitomycin C during
the first course of 5-FU. The remaining nine
patients received either cisplatin or capecitabine
based on their performance status. Radiotherapy
consisted of a daily dose of 1.8 Gy up to a total
dose of 45 Gy (twenty-five fractions in 5 weeks)
by external beam irradiation on the anoperineal
region, including the perirectal nodes. Up to an
additional 63 Gy boost radiation was given,
depending on the response and gross residual
Table 1. Patient and Tumor Characteristics
Patients (n = 50) %
Sex
Male : female ratio 1 : 1.9
Median age (yrs) 67 (39 - 81)
HIV positivity 0 0.0
Pathology subtypes
Squamous
Cloacogenic
Adenocarcinoma
33
9
8
66.0
18.0
16.0
Tumor size (clinical)
T1
T2
T3
T4
13
27
8
2
26.0
54.0
16.0
4.0
Nodal involvement (clinical)
N0
N1
N2
N3
31
10
8
1
62.0
20.0
16.0
2.0
Metastatic disease
M0
M1
46
4
92.0
8.0
Performance status
ECOG 1
ECOG 2
46
4
92.0
8.0
HIV, human immunodeficiency virus, ECOG, Eastern
Cooperative Oncology Group.Anal Canal Carcinoma in Korea
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disease. When inguinal lymphadenopathy was
present in the patient, the entire inguinal chain
including iliac lymph nodes were irradiated with
45 Gy using a anteroposterior/posteroanterior
(AP/PA) technique with a narrower PA field
covering the true pelvis.
Statistical analysis
Overall survival (OS) and relapse-free survival
(RFS) were estimated using the Kaplan-Meier
product-limit method. OS was measured from the
date of diagnosis to the date of death or the last
follow-up visit. RFS was calculated from the date
of diagnosis to the first documented relapse in
patients who attained CR. Statistical differences in
survival rates were compared using log-rank
analysis. Continuous biological variables were
dichotomized. P-values less than 0.05 were consi-
dered statistically significant.
RESULTS
The median age at presentation was 67 years
(range, 39 - 81 years). The patients had the
following disease histologies: 33 squamous cell
carcinomas (66.0%), 9 cloacogenic (18.0%), and 8
adenocarcinomas (16.0%). Cloacogenic carcinomas
were predominant in females (7/9, 77.7%), while
squamous cell carcinomas and adenocarcinomas
did not show sexual preponderance (Table 1). At
the time of diagnosis, 31 patients (62.0%) had
locally advanced disease and 4 patients (8.0%) had
distant metastases. Of the 31 patients with locally
advanced disease, 18 (36.0%) had metastases to
the perirectal (N1), inguinal lymph nodes (N2),
and/or the internal iliac lymph nodes as detected
by clinical examination and/or imaging studies.
There were no treatment related morbidities re-
quiring hospitalization and no deaths were
recorded. 4 patients were tested for human pa-
pilloma virus and 2 out of these 4 patients (50%)
tested positive for the virus.
The primary treatment modalities for the 50
patients are presented in Table 2. Thirty-seven
patients (74.0%) received the definitive CCRT as
their initial treatment. Twenty-eight patients
(75.7%) received concomitant radiotherapy with
5-FU and mitomycin C. Five patients (13.5%) were
treated concomitantly with 5-FU and cisplatin
during radiotherapy. Four patients (10.8%) re-
ceived radiotherapy with daily oral administration
of capecitabine alone due to poor performance
status. Four patients (8%) underwent abdomino-
perineal resection as their initial treatment. The
reasons for primary surgical intervention were
due to patients’ refusal, for complications such as
recto-vaginal fistula, or for unknown reasons.
The 5-year and 10-year survival rates for the 38
patients with early and locally advanced squa-
mous cell carcinoma and cloacogenic carcinoma
were 74.8% and 66.5%, respectively. The 5-year
survival and DFS of the 31 patients who received
CRT were 83.6% and 74.3% respectively. The
overall survival and DFS could not be determined
in the adenocarcinoma patient group due to the
small number of cases (n = 8). No notable dif-
ference was found in the overall survival between
the squamous cell and cloacogenic carcinoma
groups and the adenocarcinoma group at the 5- or
10-year time points (p = 0.485).
After definitive chemoradiotherapy, thirty-one
patients (83.7%) achieved complete response. Four
of the 31 patients (12.9%) who initially achieved
complete response had recurrences. All of these 4
Table 2. Primary Treatment Modalities according to
Cell Types
Primary treatment
Patients
(n = 50)
%
Squamous & cloacogenic (n = 42)
Abdominoperineal resection 3 8.0
Concurrent CRT 31 74.0
RT alone 2 4.0
Chemotherapy alone 1 2.0
Palliative chemotherpy 2 4.0
Palliative CRT 1 2.0
Best supportive care 2 2.0
Adenocarinoma (n = 8)
Abdominoperineal resection 1 2.0
Concurrent CRT 6 12.0
Palliative RT 1 2.0Won-Suk Lee, et al.
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patients recurred at distant sites; three of these
patients had liver metastases. Two (33.3%) of the
patients with recurrences were treated by
palliative APR to relieve symptoms, one patient
(16.7%) had palliative chemotherapy, and one
patient (16.7%) had palliative radiation therapy,
Three patients (8.1%) had partial responses and 3
patients demonstrated primary resistance to
chemoradiation therapy. Four patients who re-
ceived primary APR were in remission at the time
of analysis. Univariate analyses indicated that the
significant parameters influencing survival were
tumor size (p = 0.04) and inguinal node status (p
= 0.04) (Table 3). Multivariate analysis showed
that inguinal node metastasis is a single inde-
pendent prognostic variable for survival (p = 0.04).
After a median follow up of 37.8 months (range,
6.6 - 136.1 months), the 5-year and 10-year
survival rates for the 46 patients with early and
locally advanced disease were 71.9% and 64.7%,
respectively (Fig. 1). The 5-year survival and
disease-free survival rates of the 37 patients who
Table 3. Univariate Analysis*
Variables Patients (n) % p value
Squamous cell and cloacogenic carcinoma (n = 38)
Age (yrs)
≥ 60
< 60
10
28
26.3
73.7
0.90
Sex
Male
Female
18
20
47.4
52.6
0.84
Tumor size
≥ 5 cm
< 5 cm
15
23
39.5
60.5
0.04
Inguinal node
Involved
Not involved
16
22
42.1
57.9
0.03
Performance status
ECOG 1
ECOG 2
34
4
89.5
10.5
0.84
Adenocarcinoma (n = 8)
Age
≥ 60
< 60
6
2
75.0
25.0
0.37
Sex
Male
Female
4
4
50.0
50.0
Tumor size
≥ 5 cm
< 5 cm
2
6
25.0
75.0
0.08
Inguinal node
Involved
Not involved
1
7
12.5
87.5
0.04
Performance status
ECOG 1
ECOG 2
8
0
100.0
0.0
CRT, chemoradiation; APR, abdominoperineal resection;
ECOG, Eastern Cooperative Oncology Group.
*stage I through III.
Fig. 1. Overall survival in patients with squamous cell
and cloacogenic carcinoma (crosses) versus adenocarci-
noma (triangles) for stage I through III (p = 0.485).
Fig. 2. Overall survival according to treatment methods (p
= 0.44). CRT, chemoradiation; APR, abdominoperinal
resection.Anal Canal Carcinoma in Korea
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received CRT were 76.9% and 69.0%, respectively.
The CRT group had a tendency towards better
survival than the APR group, although this
difference was not statistically significant (p =0.44)
(Fig. 2).
DISCUSSION
With a median patient age of 67 years (range:
39 - 81 years) and patient group that is predo-
minantly made up of women, our patient group
is similar to the patient groups in previous
studies.
2,3,5-7,9 HIV positive homosexual males have
a 36% increased incidence of anal cancer.
10,11 None
of the Korean patients were HIV positive,
probably due to a very low incidence of HIV
positive patients (less than 0.1%) in the country.
The initial outcome for 37 patients with
locoregional disease who had been treated with
concurrent CRT are consistent to the outcomes
previously reported in the literature.
5,6,12-15 We
observed a CR rate of 83.7%, which is comparable
to other published series.
5,6,12-14 Interestingly, pati-
ents with an initial tumor size of less than 5 cm
had a tendency towards higher treatment res-
ponse (87.1%), although this tendency was not
statistically significant (p = 0.17). The 5-year sur-
vival rate for the subset of patients with squamous
and cloacogenic carcinomas was 74.8% in our
series, which is slightly higher than the 5-year
survival rates reported in the EORTC and
UKCCCR trials (3 year survival of 72% and 65%,
respectively).
5,6
The primary anal adenocarcinoma histologi-
cal subtype is a rare tumor accounting for only
16.5% of all anal cancers.
15,16 The 6 patients with
evaluable disease at the start of therapy had T1
and T2 lesions and achieved complete response.
None of the patients developed recurrent or
metastatic disease. If an accurate diagnosis can
be made, one can speculate that anal adenocar-
cinoma is analogous to other anal canal tumors
and thus chemoradiation therapy can be recom-
mended for anal adenocarcinoma patients. No
survival difference was found when patients
with squamous cell carcinoma and cloacogenic
carcinoma patients were combined and compared
to anal adenocarcinoma patients (p = 0.17).
The two significant factors that were found by
univariate analysis to influence the survival of
squamous cell carcinoma and cloacogenic car-
cinoma patients were tumor size and inguinal
lymph node metastases (p = 0.04 and p = 0.04).
These findings are in agreement with other
studies that reported tumor size and lymph node
status are strong predictors of the initial response
to treatment and survival.
2,3,5-7,9,17 While the tumor
size is an independent prognostic factor, this
finding reflects that larger tumors are more likely
to involve regional lymph nodes,
17 which are
known to be associated with local recurrences and
salvage surgical resections and thus, reduced
survival rates.
1,17,18
Although distant metastasis is uncommon at
presentation,
19 we observed that 8% of the pati-
ents had distant metastasis at the time of
diagnosis and 18% of the patients had inguinal
node metastases. The UKCCCR Anal Cancer Trial
Working Party reported
5 that 40% of the cancer
deaths occurred with disease that had been
identified outside the pelvis. Further studies need
to focus on improving systemic control of the
disease. In particular, cisplatin-based regimens
should be further investigated since Hung et al.
20
recently reported a promising application of this
drug for anal carcinoma. Currently, a randomized
Radiation Therapy Oncology Group (RTOG)
phase III trial is comparing 5-FU and mitomycin
C with 5-FU and cisplatin in a multimodal
approach combined with radiotherapy. The value
of substituting cisplatin for mitomycin in com-
bination-therapy regimens is currently being
investigated.
Acceptance of CRT as the “gold standard” for
anal cancer treatment not only achieved excellent
short- and long-term results, but also improved
the quality of life by reducing aggressive surgi-
cal approaches and by decreasing the adverse
effects associated with high dose radiother-
apy.
5,6,17,21 The CRT subsequently led to a higher
local control rate and preservation of anal
sphincter function in a great majority of the
patients. As a result, surgery is no longer the
treatment of choice, but has become a salvage
therapy for the patients who did not achieve CR.
Because of the rarity and complexity of anal
canal cancer, interdepartmental cooperation isWon-Suk Lee, et al.
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required for patient treatment, thus a team-
approach should be available for proper patient
treatment. Anal cancer screening and prevention
are gaining more acceptance in the clinic, but
require further study.
11,17,22
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